RPRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Repros Therapeutics, Inc.'s quarterly cash and cash equivalents declined from Jun. 2013 ($87.70 Mil) to Sep. 2013 ($81.83 Mil) and declined from Sep. 2013 ($81.83 Mil) to Dec. 2013 ($75.81 Mil).
Repros Therapeutics, Inc.'s annual cash and cash equivalents increased from Dec. 2011 ($4.57 Mil) to Dec. 2012 ($24.21 Mil) and increased from Dec. 2012 ($24.21 Mil) to Dec. 2013 ($75.81 Mil).
Cash and cash equivalents on banks book.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Repros Therapeutics, Inc. Annual Data
Repros Therapeutics, Inc. Quarterly Data